Engineering Medicines To Improve Patient Care Todd James SVP, Corporate Affairs and Investor Relations Todd is Senior Vice President (SVP) of Corporate Affairs and Investor Relations (IR) and a member of the Executive Team at Viridian Therapeutics. He joined Viridian in 2022. Prior to joining Viridian, Todd was SVP, Corporate Affairs and IR and a member of the Executive Committee at Acceleron Pharma up until its acquisition by Merck for $11.5 billion in late-2021. While at Acceleron from 2015 to 2021, he built the company’s in-house team and capabilities in investor relations and corporate and internal communications. He was also responsible for overseeing patient advocacy, government affairs, public relations, and corporate social responsibility. Prior to Acceleron, Todd spent 9 years at Trout Group/Trout Capital, an investor relations, broker-dealer, and strategic advisory firm dedicated to the biopharmaceutical industry. He began his career on Wall Street as part of the Biotechnology Capital Markets Intelligence Team within the Corporate Group at Thomson Financial. For three consecutive years (2019 to 2021), Todd was named to Institutional Investor Magazine’s All-America Executive Team as Best IR Professional in Biotechnology and was ranked #1 in the 2020 poll for small and mid-cap companies. In 2016, he was part of NIRI’s inaugural class of Investor Relations Charter (IRC) credential recipients. Todd graduated with a degree in Financial Economics from Moravian University.